跳至主要内容
临床试验/NCT02071563
NCT02071563已完成不适用

Food Aid Quality Review Phase II Effectiveness Study: Preventing MAM and Stunting in Burkina Faso

Tufts University1 个研究点 分布在 1 个国家目标入组 6,039 人开始时间: 2014年3月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
6,039
试验地点
1
主要终点
Incidence of MAM and Stunting

研究概览

简要总结

This research will serve as a follow-up on the review of Title II commodities performed by the Food Aid Quality Review at Tufts University in October 2011. The study in Burkina Faso will test the relative effectiveness and cost effectiveness of four supplementary foods in the prevention of MAM and stunting in normal programmatic settings.

The aims of this study are to:

  1. To compare the effectiveness of four alternative supplementary food commodities in preventing stunting and wasting, and promoting linear growth in children 6 - 23 months in the context of a preventive supplementary feeding program in Burkina Faso.
  2. To estimate the relative cost of implementing the supplementary feeding program using each commodity
  3. To estimate the relative cost/effectiveness of implementing the program using each commodity.

详细描述

Phase II of FAQR in Burkina Faso will assess the recommended improvements in the four arms of the study: CSB14 prepared with FVO, RUSF1, CSB+, and SC+.

The study will be a cluster-randomized, effectiveness trial. The study will use a mixed method technique of quantitative and qualitative data collection. The design of the study is quasi-experimental: food distribution sites (FDPs) (and the communities they serve) will be grouped into four clusters that are geographically contiguous with each other and sufficiently distant from each other so that the Beneficiaries are unlikely to have contact with each other. The four groups of food distribution points will be randomly assigned to one of four arms, defined by the specific food to be provided:

  1. Corn Soy Blend 14 (CSB14) (with whey protein concentrate and enhanced micronutrient profile), prepared with fortified vegetable oil (FVO); 75g CSB14/day, 22.5g FVO/day
  2. Ready-to use supplementary food 1 (RUSF1); 100g RUSF/day
  3. Super Cereal Plus (SC+)( has an enhanced nutrient profile, non-fat dry milk, and oil already embedded into the CSB); 122g SC+/day
  4. Corn Soy Blend Plus (CSB+) prepared with FVO; 75g CSB+/day, 22.5g FVO/day The CSB+ arm will act as a control

The intervention is implemented using the food distribution points providing supplementary food (CSB14, CSB+, RUSF, SC+) to children once they reach six months of age, and children from 6 to 23 months. This study will enroll all children as they turn six months of age and follow them through their 23rd month of age. Variables to be tracked include: age, sex, arm of study/commodity received ,Mid-Upper Arm Circumference (MUAC), height for age, weight for age, weight for height, month-to-month linear growth and weight gain, incidence of stunting (height for age below -2 Standard Deviations (SD)), incidence of wasting (weight for height below - 2 SD).

At 24 months, children stop receiving supplementary food. The study will continue to monitor these variables for at least an additional 6 months (through the age of 30 months).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
6 Months 至 23 Months(Child)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

CSB14

Active Comparator

Isocaloric amount and cost-effectiveness of CSB14 (with whey protein concentrate and enhanced micronutrient profile), prepared with fortified vegetable oil (FVO).

干预措施: CSB14 (Dietary Supplement)

RUSF1

Active Comparator

Isocaloric amount and cost-effectiveness of Ready-to Use Supplementary Food 1(RUSF1), USAID's Lipid-Based Nutrient Supplement (LNS) product

干预措施: RUSF1 (Dietary Supplement)

SC+

Active Comparator

Isocaloric amount and cost-effectiveness of Supercereal Plus (SC+), the FBF used by WFP, which has an enhanced nutrient profile, dairy ingredient (non-fat dry milk), and oil already embedded into the flour

干预措施: SC+ (Dietary Supplement)

CSB+

No Intervention

Isocaloric amount and cost-effectiveness of Supercereal/CSB+ prepared with FVO.

结局指标

主要结局

Incidence of MAM and Stunting

时间窗: Monthly for 18 months

Primary outcomes to be measured are incidence of MAM and incidence of stunting during the 18 months of preventive supplementation (age 6 months to 23 months). Stunting will be defined as less than -2 SD of Height-for-Age Z-score and MAM will be defined as less than -2 SD Weight-for-Height (length) Z-score

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
不适用
ESTUDIO FASE II PARA VALORAR LA EFICACIA Y SEGURIDAD DEL RECAMBIO PLASMÁTICO CON ALBÚMINA 5% EN EL ACLARAMIENTO DEL PÉPTIDO BETA-AMILOIDE EN LÍQUIDO CEFALORRAQUÍDEO, Y SUS EFECTOS EN PACIENTES CON ENFERMEDAD DE ALZHEIMER LEVE-MODERADAEnfermedad de Alzheimer, leve a moderada
EUCTR2007-000414-36-ESInstituto Grifols, S.A.
进行中(未招募)
不适用
Estudio para evaluar la eficacia y seguridad del tratamiento del estudio como primera linea de tratamiento en pacientes con cáncer gástrico Her 2 positivoCáncer GástricoMedDRA version: 14.0Level: LLTClassification code 10001150Term: Adenocarcinoma gastricSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2011-001231-23-ESFundación para el Progreso de la Oncología en Cantabria
进行中(未招募)
1 期
Estudio de fase II para evaluar la eficacia y la seguridad de la quimiorradioterapia con 5-fluorouracilo, mitomicina C y panitumumab como tratamiento del carcinoma anal de células escamosas
EUCTR2010-018430-48-ESGrupo Español Multidisciplinar en cáncer Digestivo-GEMCAD
进行中(未招募)
不适用
Ensayo de fase II para evaluar la eficacia y la seguridad de panitumumab combinado con docetaxel y cisplatino como tratamiento de primera línea del adenocarcinoma gástrico o de la unión gastroesofágica en estadio avanzado - SPIGAEnsayo fase II para evaluar la eficacia y seguridad de panitumumab combinado con docetaxel y cisplatino como tratamiento de primera línea del adenocarcinoma gástrico o de la unión gastroesofágica en estado avanzado.
EUCTR2010-021192-87-ESGrupo Gallego de Investigación en Oncología - GGIO
进行中(未招募)
1 期
Estudio fase II abierto, para valorar la eficacia y tolerabilidad de ZD6474 (ZACTIMA® ) 100 mg en Monoterapia en pacientes con Cáncer de Tiroides Medular Hereditario Metastásico o Localmente Avanzado
EUCTR2006-001354-28-ESAstraZeneca AB22